Xoma's acquisition of the royalty and milestone rights for Arimoclomol and Aldoxorubicin from LadRx for $5 million directly impacts the company's portfolio and potential revenue streams. The acquisition targets orphan disease Niemann-Pick disease type C and Phase 2 oncology, which could lead to increased revenue and growth for Xoma.